Savara Inc. (SVRA) Upgraded to Buy After FDA CMC Breakthrough

Savara Inc. (NASDAQ:SVRA) is among the best US stocks under $10 to invest in. H.C. Wainwright has raised the price target on Savara Inc. (NASDAQ:SVRA) to $5.00 from $2.00, while upgrading the stock from Neutral to Buy. Much of this optimism is driven by the company’s agreement with the FDA on Chemistry, Manufacturing, and Controls (CMC) data requirements.

During a Type A meeting, Savara Inc. (NASDAQ:SVRA) resubmitted a Biologics License Application (BLA) for Molbreevi, after being refused a File letter from the agency. Andrew Fein, an analyst at H.C. Wainwright, sees improved results for the company’s BLA, which is set to be resubmitted in December.

Replacing the previous drug substance manufacturer, GEMA Biotech, the filing now includes Fujifilm Diosynth Biotechnologies. Many believe it to be a “make it or break it” event, and certainly, the company now appears poised to make it.

Savara Inc. (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company based in Pennsylvania that provides solutions for rare respiratory diseases. Founded in 2007, the company is committed to developing innovative therapies to improve the lives of many.

While we acknowledge the potential of SVRA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.